Nanoscope Therapeutics Will Present Data in Vienna
The company is scheduled to share new clinical trial results at two international medical conferences starting September 30.
Updated on Sept. 23, 2026 in Biotech
Nanoscope Therapeutics will debut new clinical trial data for its macular degeneration and retinitis pigmentosa programs at upcoming events in Vienna. The findings will be shared starting September 30, 2026, at the Retina Forum 2026 and the 26th Euretina Congress.
Why it matters
These presentations provide a public update on the efficacy and long-term development of optogenetic therapies. Sharing this clinical data is essential for transparency and progress in treating degenerative eye conditions.
The data release includes results from a 4-year extension study focusing on the long-term impacts of the MCO-010 therapy for retinitis pigmentosa. Additional results will cover the sonpiretigene isteparvovec optogenetic therapy.
The players
Nanoscope Therapeutics
This is a biotech company focused on developing optogenetic gene therapies for inherited and age-related retinal diseases.
Jordi Mones
He is a researcher scheduled to present randomized controlled trial data regarding sonpiretigene isteparvovec therapy.
Benjamin Bakall
He is a medical professional presenting findings from a 4-year extension study on MCO-010 therapy.
Samarendra Mohanty
He is a company official set to deliver a presentation on behalf of Nanoscope Therapeutics at the Retina Forum 2026.
Samuel Barone
He is a participant scheduled to join a panel discussion regarding geographic atrophy and intermediate AMD.
The details
Company executives and lead researchers will present at the VIECON - Vienna Congress & Convention Center to discuss recent findings from randomized controlled trials. These sessions aim to provide clinical insights into the progress of therapies targeting intermediate AMD and geographic atrophy.
Timeline
Retina Forum 2026 is scheduled to take place on September 30, 2026.
The 26th Euretina Congress will occur from October 1 to October 4, 2026.
The Big Picture
The clinical updates regarding the MCO-010 therapy for retinitis pigmentosa represent a key milestone in the maturation of gene-based ocular treatments. This presentation helps bridge the gap between initial laboratory testing and long-term therapeutic viability.
For patients and medical practitioners, these disclosures offer a clearer picture of potential future treatment timelines and therapy efficacy. The outcomes eventually influence which optogenetic treatments move closer to clinical availability for those with degenerative vision loss.
The takeaway
Clinical trial disclosures are critical for moving experimental therapies toward regulatory approval and eventual patient care. Patients should track these reports to stay informed on the evolving landscape of sight-saving medical technology.
Further reading
Learn more about the latest developments in the field by visiting our Biotech section.
